PROMISING INDICATIONS FROM SCANDIVIR

(NGM:SCN)

Recent results from studies conducted by Scandivir AB, subsidiary to Scandinavian Clinical Nutrition AB (SCN), indicate that a method to test for Ad-36 infection (the “obesity virus”) may be within reach.

The development of a simple and rapid analysis methodology to screen large numbers of patients and see if they are infected with the “obesity virus” Ad-36 has been a top priority within Scandivir AB since the formation of the company in April, 2008. Recent data suggest that this goal may be within reach.

Pilot studies investigating human serum samples and comparing them to the existing serum neutralization assay still need to be confirmed, but look promising in terms of correlation between the results from the two methods. If the indicative results prove to be correct, the company will start developing a test for professional use, and also initiate R&D work on a test kit for home use.

For more information, please contact:

Dan Edwall, VP R&D at SCN, de@scnutrition.com, +46 707 98 80 89

Anders Struksnes, VP Business Development at Scandivir, +47 911 98 942

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).For more information, please visit www.scnutrition.com.